June 2019
TBC

 

Power Your Antibody-Drug Conjugate into Clinical Development

Focused on ADC drug development, the inaugural World ADC Asia will enable you to propel your antibody-drug conjugate pipeline into clinical development.  Join 80+ ADC experts from the world’s leading ADC companies at this forum to network with potential collaborators and further cement existing partnerships.

Designed with AbGenomics, Roche and RemeGen and other leading ADC organisations this forum will enable you to explore novel linker technologies for enhanced in vivo stability, confidently meet regulatory quality specifications for biosimilar candidates and confidently outsource to your chosen CMO.

This is the only ADC focused conference that will bring together all the key players both from within  Asia, the US and Europe.

“The conference is an awesome opportunity to learn what has been happening and also what to expect in the future, from both technology and business perspective”
MilliporeSigma

“The World ADC meetings organized by Hanson Wade provide for superb networking for the scientific community working on ADCs within Biotech, Pharma and Academia.”
ImmunoGen

“Reports from the early clinical trials indicate that ADCs are setting the bar very high for eliminating cancer and the conference emphasised this exciting development.”
Eisai

“This conference is an unique opportunity to talk about ADCs deeply. It was really fruitful.”
Daiichi Sankyo

 
Media Partner